BCX-1777
BCX-1777
BCX-1777 (pronunciation: B-C-X-1777), also known as forodesine, is a transition state analogue inhibitor that has been used in the experimental treatment of T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL).
Etymology
The name BCX-1777 is derived from the code assigned to it during its development phase by BioCryst Pharmaceuticals. The alternative name, forodesine, is a combination of the Latin word 'foro', meaning 'to bore through', and 'desine', meaning 'to cease', reflecting its function as a drug designed to halt the progression of certain types of cancer.
Mechanism of Action
BCX-1777 works by inhibiting the enzyme purine nucleoside phosphorylase (PNP), which plays a crucial role in the survival of T-cells. By inhibiting PNP, BCX-1777 disrupts the metabolic processes of the T-cells, leading to their death and thus slowing the progression of T-cell related cancers.
Related Terms
- Transition state analogue
- T-cell
- Acute lymphoblastic leukemia
- Cutaneous T-cell lymphoma
- Purine nucleoside phosphorylase
- BioCryst Pharmaceuticals
External links
- Medical encyclopedia article on BCX-1777
- Wikipedia's article - BCX-1777
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski